0001171000-15-000047.txt : 20150702 0001171000-15-000047.hdr.sgml : 20150702 20150702135528 ACCESSION NUMBER: 0001171000-15-000047 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150701 FILED AS OF DATE: 20150702 DATE AS OF CHANGE: 20150702 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Nexvet Biopharma plc CENTRAL INDEX KEY: 0001618561 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: NATL INST FOR BIOPROCESSING RESEARCH STREET 2: FOSTERS AVENUE, MOUNT MERRION CITY: BLACKROCK CO. DUBLIN STATE: L2 ZIP: 00000 BUSINESS PHONE: 353 1 215 8100 MAIL ADDRESS: STREET 1: NATL INST FOR BIOPROCESSING RESEARCH STREET 2: FOSTERS AVENUE, MOUNT MERRION CITY: BLACKROCK CO. DUBLIN STATE: L2 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: NEXVET BIOPHARMA Ltd DATE OF NAME CHANGE: 20140903 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GEARING DAVID CENTRAL INDEX KEY: 0001632481 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36828 FILM NUMBER: 15968633 MAIL ADDRESS: STREET 1: C/O NEXVET BIOPHARMA PLC STREET 2: NATL INST, FOSTERS AVENUE, MOUNT MERRION CITY: BLACKROCK STATE: L2 ZIP: 00000 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2015-07-01 0001618561 Nexvet Biopharma plc NVET 0001632481 GEARING DAVID C/O NEXVET BIOPHARMA PLC NIBRT; FOSTERS AVENUE, MOUNT MERRION BLACKROCK, CO. DUBLIN L2 IRELAND 0 1 0 0 CHIEF SCIENTIFIC OFFICER Ordinary Shares 2015-07-01 4 M 0 3734 .125 A 264526 I By Gearing Family Pty Ltd <Gearing Family A/C> Ordinary Shares 5600 D Ordinary Shares 83664 I By DJGearing Pty Ltd <Gearing Family Superannuation Fund A/C> Options to purchase shares .125 2015-07-01 4 M 0 3734 0 D 2015-07-01 2019-07-01 Ordinary Shares 3734 13066 I By Gearing Family Pty Ltd <Gearing Family A/C The reporting person and his spouse share voting and dispositive power with respect to these reported securities. 3,734 options vested and became exercisable on 7/1/15; 3,733 options will vest and be exercisable on each of 7/1/16 and 7/1/17. The remaining 5,600 options will vest and be exercisable upon successful completion of an efficacy trial for any Issuer product, as determined by the Issuer's board of directors; such completion must occur on or before 7/1/19. s/ David Gearing by Geraldine T. Farrell, Attorney-in-Fact 2015-07-02